Wanling Xie

22PUBLICATIONS
261CO-AUTHORS
Molecular targetsRadiation therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Aug 24, 2026
A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.

|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.

|May 07, 2026
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).

|Apr 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer.

|Dec 13, 2025
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Rana R McKay, Sumanta Pal, Wanling Xie

|Jul 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.

Charlene M Mantia, Opeyemi A Jegede, David F McDermott

Pageof 4

Frequent Collaborators

12 joint publications

Toni K Choueiri

9 joint publications

Rana R McKay

7 joint publications

David F McDermott

5 joint publications

Bradley McGregor